

PBS LISTS AUGTYRO® (REPOTRECTINIB) FOR THE TREATMENT OF ADULT PATIENTS WITH ROS1-POSITIVE NON-SMALL CELL LUNG CANCER

(AUSTRALIA, Melbourne, 1 April 2026) - Bristol Myers Squibb Australia (BMSA) today announced the Pharmaceutical Benefits Scheme (PBS) has listed AUGTYRO® (repotrectinib) for the treatment of Stage IIIB (locally advanced) or Stage IV (metastatic) ROS1-positive non-small cell lung cancer (NSCLC).^{1,2}

Lung cancer is estimated to be the fourth most commonly diagnosed cancer in Australia in 2025³ and remains the leading cause of cancer-related death nationally³. NSCLC accounts for approximately 64% of all lung cancer cases in men and 61% in women⁴. ROS1-positive NSCLC is a rare subset, estimated to occur in approximately 1-2% of patients with NSCLC⁵.

“The PBS listing of AUGTYRO is another important milestone for BMSA and it underscores our commitment to people living with rare lung cancer,” said Owen Smith, General Manager BMS Australia and New Zealand. “We continue to invest in research and development in areas of significant unmet need, and we remain committed to bringing forward medicines that are appropriately evaluated, registered and publicly funded for the communities we serve.”

Australian patients from leading cancer centres contributed to the clinical trial that supported the evaluation of AUGTYRO, reflecting local involvement in the global development of treatments for rare forms of lung cancer⁶.

“It is encouraging to see a PBS listing for people diagnosed with ROS1-positive advanced or metastatic NSCLC,” said Prof Ben Solomon of Peter MacCallum Cancer Centre, Victoria. “Molecular testing identifies the genetic features that define different types of lung cancer, including ROS1 fusions. Accurate identification of these features helps clinicians understand the nature of a person’s cancer and personalise therapy by selecting the appropriate treatment for their specific diagnosis.”

Lung Foundation Australia’s General Manager, Policy, Advocacy and Prevention, Paige Preston, said the listing provides an important new treatment option for people with ROS1-positive NSCLC. “We welcome the PBS listing of AUGTYRO as an additional treatment option for people with ROS1-positive NSCLC,” Ms Preston said. “For those affected by rare cancers, timely access to publicly funded treatments is especially important so that these communities are not left behind.”

About AUGTYRO (repotrectinib)

AUGTYRO is a second-generation tyrosine kinase inhibitor (TKI) that targets ROS1 gene fusion proteins driving NSCLC¹.

Indication: AUGTYRO, as monotherapy, is indicated for the treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)¹.

Like all medicines, AUGTYRO can cause side effects. Some side effects can be serious and may require medical attention⁷. The most common ($\geq 20\%$) side effects observed with AUGTYRO are change of taste, sensations like numbness, tingling or burning, constipation, feeling tired, major change in thinking patterns, nausea, muscle weakness, headache, sleep disorders, increased blood levels of enzyme from muscle, weight gain, joint pain, vomiting, vision disorders, loose or frequent stools, muscle pain, leg and/or arm pain.

For more information, please refer to the Consumer Medicine Information (CMI) for AUGTYRO ([repotrectinib](#)).

Disclosure

Bristol Myers Squibb supports disclosure and transparency on interactions between the healthcare industry and healthcare professionals to ensure public trust and confidence. No expert spokespeople have been offered compensation for their involvement in this medical media campaign. All expert spokespeople have been briefed on the approved use of this product and their obligations with regard to promotion to the medical profession.

About Bristol Myers Squibb™

Bristol Myers Squibb™ is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb™, visit us at [BMS.com](#) or follow us on [LinkedIn](#), [Twitter](#), [YouTube](#), [Facebook](#) and [Instagram](#).

Bristol Myers Squibb: Creating a Better Future for People with Cancer

Bristol Myers Squibb is inspired by a single vision – transforming patients' lives through science.

The goal of the company's cancer research is to deliver medicines that offer each patient a better, healthier life, and to make cure a possibility.

Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalised medicine and, through innovative digital platforms, are turning data into insights that sharpen their focus. Deep understanding of causal human biology, cutting-edge capabilities, and differentiated research platforms uniquely position the company to approach cancer from every angle.

Cancer can have a relentless grasp on many parts of a patient's life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship. As a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.

Further information is available on request from Bristol Myers Squibb Australia Pty Ltd, ABN 33 004 333 322, Level 2, 4 Nexus Court, Mulgrave, VIC, 3170. ™ Trademark. Veeva number: 3600-AU-2600021. Prepared: March 2026.

ends#

MEDIA ENQUIRIES

Emma Nunan | Ogilvy Health

E: emma.nunan@ogilvy.com | P: 0421 429 584

Alison Melville, Bristol-Myers Squibb™

E: alison.melville@bms.com | P: 0477 309 012

1. AUGTYRO® (repotrectinib) Product Information (<https://rss.medsinfo.com.au/bq/pi.cfm?product=bqpaugtyr>).
2. Pharmaceutical Benefits Schedule. Available at: <http://www.pbs.gov.au>
3. Australian Institute of Health and Welfare. Overview of cancer in Australia. Australian Institute of Health and Welfare. [Online] February 11, 2025. <https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/overview#lung>.
4. Australian Institute of Health and Welfare & Cancer Australia 2011. Lung cancer in Australia: an overview. Available at: <https://www.aihw.gov.au/reports/cancer/lung-cancer-in-australia-overview/summary>. Accessed March 2026

5. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. *J Clin Oncol* 2012; 30: 863-70.
6. ClinicalTrials.gov: NCT03093116. A study of repotrectinib (TPX-0005) in patients with advanced solid tumors harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1). Available at <https://classic.clinicaltrials.gov/ct2/show/NCT03093116>. Accessed March 2026
7. AUGTYRO® (repotrectinib) Consumer Medicine Information summary (<https://rss.medsinfo.com.au/bq/cmi.cfm?product=bqcaugtyr>)